trial

A Study of Paliperidone Palmitate 6-Month Formulation

NCTId NCT03345342
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 841 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2020-05-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
841 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-11-20
Primary completion
2020-05-08
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
PP6MPP3M 350 mg eq.PP3M 525 mg eq.PP1M

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

138 total
Rogers, United StatesAnaheim, United StatesCosta Mesa, United StatesGarden Grove, United StatesLemon Grove, United StatesOakland, United StatesSan Rafael, United StatesHialeah, United StatesMiami, United StatesMiami, United StatesTampa, United StatesAtlanta, United States

Linked catalysts

1
A Study of Paliperidone Palmitate 6-Month Formulation — primary completion2020-05-08

Facts & assertions

4 sourced
Enrollment
841
Phase
PHASE3
Primary Completion Date
2020-05-08
Status
COMPLETED
relationships
The graph out of here
drug
PP6M
drug
PP3M 350 mg eq.
drug
PP3M 525 mg eq.
drug
PP1M
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication